BioCryst Pharmaceuticals, Inc. financial reports, BioCryst Pharmaceuticals, Inc. annual revenue in 2024. When does BioCryst Pharmaceuticals, Inc. report revenue?
BioCryst Pharmaceuticals, Inc. total revenue, net income and dynamics of changes in US dollar today
BioCryst Pharmaceuticals, Inc. current income and income for the latest reporting periods. Net revenue BioCryst Pharmaceuticals, Inc. is now 19 059 000 $. Information about net revenue is taken from open sources. The dynamics of BioCryst Pharmaceuticals, Inc. net revenue grew by 15 043 000 $ compared to the previous report. Chart of online financial report of BioCryst Pharmaceuticals, Inc.. The financial report chart shows the values from 30/06/2017 to 31/03/2021. BioCryst Pharmaceuticals, Inc. total revenue on the graph is shown in yellow.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
19 059 000 $
+223.75 % ↑
-64 284 000 $
-
31/12/2020
4 016 000 $
+47.16 % ↑
-60 493 000 $
-
30/09/2020
6 102 000 $
+243.77 % ↑
-46 115 000 $
-
30/06/2020
2 871 000 $
+98.27 % ↑
-38 607 000 $
-
30/09/2019
1 775 000 $
-
-37 592 000 $
-
30/06/2019
1 448 000 $
-
-37 629 000 $
-
31/03/2019
5 887 000 $
-
-31 054 000 $
-
31/12/2018
2 729 000 $
-
-27 432 000 $
-
30/09/2018
1 454 000 $
-
-29 597 000 $
-
30/06/2018
12 494 000 $
-
-18 446 000 $
-
31/03/2018
3 976 000 $
-
-25 777 000 $
-
31/12/2017
3 890 000 $
-
-19 543 000 $
-
30/09/2017
8 760 000 $
-
-15 134 000 $
-
30/06/2017
3 099 000 $
-
-16 886 000 $
-
Show:
to
BioCryst Pharmaceuticals, Inc. financial report charts
Dates of BioCryst Pharmaceuticals, Inc. finance reports: 30/06/2017, 31/12/2020, 31/03/2021. The dates of the financial statements are determined by the accounting rules. The latest date of the financial report of BioCryst Pharmaceuticals, Inc. is 31/03/2021. Gross profit BioCryst Pharmaceuticals, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit BioCryst Pharmaceuticals, Inc. is -29 263 000 $
BioCryst Pharmaceuticals, Inc. quarterly report dates
Cost of revenue BioCryst Pharmaceuticals, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue BioCryst Pharmaceuticals, Inc. is 48 322 000 $ Total revenue BioCryst Pharmaceuticals, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue BioCryst Pharmaceuticals, Inc. is 19 059 000 $ Operating income BioCryst Pharmaceuticals, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income BioCryst Pharmaceuticals, Inc. is -51 377 000 $
Net income BioCryst Pharmaceuticals, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income BioCryst Pharmaceuticals, Inc. is -64 284 000 $ Current assets BioCryst Pharmaceuticals, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets BioCryst Pharmaceuticals, Inc. is 273 771 000 $ Total assets BioCryst Pharmaceuticals, Inc. refers to the total amount of assets owned by a person or entity. Total assets BioCryst Pharmaceuticals, Inc. is 284 431 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
30/09/2018
30/06/2018
31/03/2018
31/12/2017
30/09/2017
30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-29 263 000 $
-31 419 000 $
-25 669 000 $
-24 627 000 $
-23 363 000 $
-26 259 000 $
-23 092 000 $
-20 772 000 $
1 436 000 $
12 251 000 $
3 836 000 $
3 761 000 $
7 503 000 $
3 077 000 $
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
48 322 000 $
35 435 000 $
31 771 000 $
27 498 000 $
25 138 000 $
27 707 000 $
28 979 000 $
23 501 000 $
18 000 $
243 000 $
140 000 $
129 000 $
1 257 000 $
22 000 $
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
19 059 000 $
4 016 000 $
6 102 000 $
2 871 000 $
1 775 000 $
1 448 000 $
5 887 000 $
2 729 000 $
1 454 000 $
12 494 000 $
3 976 000 $
3 890 000 $
8 760 000 $
3 099 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
1 775 000 $
1 448 000 $
5 887 000 $
2 729 000 $
1 454 000 $
12 494 000 $
3 976 000 $
3 890 000 $
8 760 000 $
3 099 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-51 377 000 $
-57 431 000 $
-42 864 000 $
-38 510 000 $
-35 098 000 $
-34 918 000 $
-29 330 000 $
-24 962 000 $
-28 493 000 $
-18 251 000 $
-22 214 000 $
-17 861 000 $
-13 349 000 $
-15 516 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-64 284 000 $
-60 493 000 $
-46 115 000 $
-38 607 000 $
-37 592 000 $
-37 629 000 $
-31 054 000 $
-27 432 000 $
-29 597 000 $
-18 446 000 $
-25 777 000 $
-19 543 000 $
-15 134 000 $
-16 886 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
-
-
-
-
-
-
-
-
22 006 000 $
21 010 000 $
18 441 000 $
16 924 000 $
17 509 000 $
15 759 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
70 436 000 $
61 447 000 $
48 966 000 $
41 381 000 $
36 873 000 $
36 366 000 $
35 217 000 $
27 691 000 $
29 929 000 $
30 502 000 $
26 050 000 $
21 622 000 $
20 852 000 $
18 593 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
273 771 000 $
323 800 000 $
162 436 000 $
203 837 000 $
78 803 000 $
103 719 000 $
117 649 000 $
114 352 000 $
-
-
104 156 000 $
125 391 000 $
175 370 000 $
92 263 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
284 431 000 $
334 715 000 $
176 226 000 $
214 706 000 $
90 500 000 $
116 344 000 $
142 338 000 $
146 841 000 $
168 308 000 $
136 644 000 $
155 372 000 $
178 259 000 $
191 492 000 $
113 509 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
226 902 000 $
272 127 000 $
96 492 000 $
173 468 000 $
29 903 000 $
30 760 000 $
34 804 000 $
26 731 000 $
-
-
48 366 000 $
50 282 000 $
117 776 000 $
39 696 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
82 169 000 $
71 948 000 $
66 326 000 $
69 477 000 $
-
-
35 365 000 $
23 289 000 $
33 372 000 $
31 460 000 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
149 478 000 $
114 484 000 $
91 307 000 $
114 397 000 $
161 624 000 $
80 673 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
131 753 000 $
125 537 000 $
119 831 000 $
97 606 000 $
-
-
53 210 000 $
26 040 000 $
54 521 000 $
54 163 000 $
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
145.58 %
107.90 %
84.19 %
66.47 %
-
-
34.25 %
14.61 %
28.47 %
47.72 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
-74 988 000 $
-19 262 000 $
33 637 000 $
76 507 000 $
-41 253 000 $
-9 193 000 $
22 507 000 $
49 235 000 $
72 873 000 $
46 184 000 $
62 054 000 $
83 767 000 $
100 632 000 $
24 076 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-27 637 000 $
-24 501 000 $
-26 998 000 $
-23 985 000 $
-
-
-19 653 000 $
-10 519 000 $
-12 430 000 $
-9 667 000 $
Last revenue report of BioCryst Pharmaceuticals, Inc. was 31/03/2021. According to last financial report total revenue in BioCryst Pharmaceuticals, Inc. was 19 059 000 US dollar and changed by +223.75% since last year. Net income in BioCryst Pharmaceuticals, Inc. was -64 284 000 $ in last quartal, net income changes to 0%.
Current cash BioCryst Pharmaceuticals, Inc. - the sum of all of the cash a company has on the date of report. Current cash BioCryst Pharmaceuticals, Inc. is 226 902 000 $
BioCryst Pharmaceuticals, Inc. stocks data
BCRX stock price
BioCryst Pharmaceuticals, Inc. stock price today, BCRX stock quote.
